WATCHMAN is a first-of-its-kind, proven alternative to long-term warfarin therapy for stroke risk reduction in patients with non-valvular atrial fibrillation. The device is delivered via a transfermoral approach and is designed to close the left atrial appendage (LAA) to prevent migration of blood clots, thus reducing the risk of stroke and systemic embolism.
WATCHMAN is engineered to conform to the unique anatomy of the LAA.
Learn more at https://www.bostonscientific.com/en-US/products/laac-system/watchman.html
There are no reviews yet.